Key Highlights
- On November 17, 2026, Novartis (NYSE:NVS) announced FDA approval of Cosentyx 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a steroid taper.
- Cosentyx is now the first and only anti-IL-17 biologic approved for the disease, marking its 11th US indication.
- In the Phase III REPLENISH trial, patients on Cosentyx were twice as likely to achieve sustained remission while tapering off steroids.
- Polymyalgia rheumatica affects about 966,000 people in the United States, and up to 40% relapse within the first year.
Opening a New Market for a Familiar Drug
Novartis (NYSE:NVS) has now won approval for Cosentyx, known generically as secukinumab, in polymyalgia rheumatica. The inflammatory condition brings pain and stiffness to the shoulders, neck and hips, and it mainly strikes people over 50. Corticosteroids have been the mainstay for decades. Though fast-acting, they carry well-known risks when taken for long periods, such as bone loss, diabetes, weight gain and infection, and many patients relapse once doses are lowered. Adults whose disease responds inadequately to corticosteroids, or who cannot tolerate a steroid taper, are covered by the label. They make up a substantial share of the roughly 966,000 Americans with the condition, since up to 40% of patients relapse in the first year. Already widely used in psoriasis, psoriatic arthritis and axial spondyloarthritis, Cosentyx works by blocking interleukin-17A, a signalling protein involved in inflammation. The new use is its 11th approved US indication and the first anti-IL-17 approval in the disease, a differentiated position for Novartis in a field with few targeted options.
Findings From the REPLENISH Trial
The approval is underpinned by REPLENISH, a global, randomized, double-blind, placebo-controlled Phase III trial run in 27 countries. Cosentyx or placebo was given with a structured steroid taper, and the endpoint was sustained remission, meaning no disease flares while coming off corticosteroids. Against placebo, Cosentyx doubled the likelihood of sustained remission while helping patients taper steroids, Novartis said, and the cumulative steroid dose that patients required was assessed as well. The approved dose is 150 mg. Lower steroid exposure matters to doctors and payers alike, as complications of long-term steroid use are costly. Europe has already approved the indication and Japan is reviewing it, so the opportunity reaches beyond the United States. A company intent on extending the life of its key franchises gains incremental Revenue from a new population of older patients with a chronic condition at fairly low additional development cost, and it also strengthens ties with rheumatologists already prescribing the drug for other conditions.
Commercial Prospects and Risks
Cosentyx ranks among the largest products in the portfolio of Novartis (NYSE:NVS), so each added indication helps defend revenue as competition grows. The polymyalgia rheumatica opportunity is meaningful but needs to be kept in perspective. Uptake hinges on whether rheumatologists will shift patients from inexpensive steroids to a costly biologic, on insurer coverage policies that may require patients to Fail steroid treatment first, and on how convenient the dosing is. Rival therapies, including an IL-6 inhibitor already approved in the disease, will compete for the same patients. Further out, biosimilar versions of Cosentyx are expected later in the decade and will weigh on pricing across every indication. For investors, the approval backs the Novartis strategy of building growth from its existing immunology Franchise while advancing newer medicines. Early prescription data in 2027 and any refreshed peak-sales commentary from management will show how much the new label contributes.
Where Things Stand
FDA approval makes Cosentyx the first anti-IL-17 biologic for polymyalgia rheumatica and adds a steroid-sparing option for a large, underserved population. It is the drug's 11th label in the United States and follows approval in Europe. Prescription uptake and payer coverage will set its commercial value.



![Arch Biopartners Inc. Turns Heads as Phase II kidney-drug development Sparks New Trading Interest on the TSXV Composite — Small Cap Growth Stock [TSXV:ARCH]](/featured_image/gallery/medium/shutterstock_2606085317_11_18_2026_16_10_43_645635.jpg)
![Vimy Pharmaceuticals Corp. Momentum Jumps as its new-listing debut Puts the TSXV Composite in Focus — Small Cap-Growth Stock [TSXV:VIMY]](/featured_image/gallery/medium/shutterstock_512538715_11_18_2026_16_11_17_989273.jpg)
![WELLSTAR Technologies Corp. Momentum Jumps as record public-company quarterly growth Puts the TSXV Composite in Focus — Small Cap-Growth Stock [TSXV:WSTR]](/featured_image/gallery/medium/shutterstock_2439951387_11_18_2026_16_11_37_467341.jpg)
Please wait processing your request...